Partial list of confirmed speakers and lecture titles.
| Name | Country | Title |
|---|---|---|
| Dag Aarsland | UK | DEMENTIA WITH LEWY-BODIES: NEW DEVELOPMENTSTE |
| Roy N Alcalay | Israel | TOWARDS PRECISION MEDICINE IN GENETIC PARKINSON'S DISEASE |
| Maria Ankarcrona | Sweden | MODULATION OF MICROGLIAL MITOCHONDRIA-ER CONTACTS TO ALLEVIATE INFLAMMATION IN ALZHEIMER'S DISEASE |
| Johannes Attems | UK | TAU IN PART, AD AND FTLD |
| Rhoda Au | USA | GETTING THERE FROM HERE: EMBRACING A DIGITAL REVOLUTION |
| Tim Bartels | UK | THE GUT-BRAIN AXIS IN SYNUCLEINOPATHIES |
| Mathew Blurton Jones | USA | HARNESSING IPSC-MICROGLIA FOR CNS-WIDE DELIVERY OF THERAPEUTIC PROTEINS |
| Per Borghammer | Denmark | BRAIN-FIRST AND BODY-FIRST SUBTYPES OF PARKINSON’S DISEASE - EVIDENCE AND IMPLICATIONS |
| Guojun Bu | Hong Kong PRC | PROTECTIVE MECHANISMS OF APOE2 AND RARE APOE VARIANTS |
| Luc Buee | France | FROM MOLECULAR INSIGHTS TO CLINICAL APPLICATIONS: TARGETING SPECIFIC TAU SPECIES |
| Ornit Chiba-Falek | USA | EMPOWERING SINGLE-CELL MULTI-OMICS IN ALZHEIMER’S RESEARCH: MECHANISTIC INSIGHTS AND TRANSLATIONAL APPLICATIONS |
| John Collinge | USA | IATROGENIC ALZHEIMER'S DISEASE AND ITS IMPLICATIONS |
| Cara Croft | UK | TARGETING TAU CLEARANCE IN ALZHEIMER'S DISEASE AND TAUOPATHIES |
| Claudio A. Cuello | Canada | ALZHEIMER’S, ABETA, TAU AND LITHIUM MICRODOSES THERAPY |
| Lis de Weerd | Germany | ANTI-A_ IMMUNOTHERAPY-MEDIATED AMYLOID CLEARANCE ATTENUATES MICROGLIAL ACTIVATION WITHOUT INDUCING EXHAUSTION AT RESIDUAL PLAQUES |
| Daniel Ferreira Padilla | Sweden | LATEST ADVANCES IN BIOMARKERS FOR DEMENTIA WITH LEWY BODIES |
| Howard Fillit | USA | BEYOND AMYLOID AND TAU: NEW TARGETS IN DEVELOPMENT |
| Nick Fox | UK | ARIA, ATROPHY AND MRI IN ANTI-AMYLOID THERAPIES |
| Dan Frenkel | Israel | THE LINK BETWEEN SENESCENT GLIA TO NEURODEGENERATION IN AD |
| Kristine Freude | Denmark | MICROGLIAL RESPONSES IN ALZHEIMER’S DISEASE: MOLECULAR AND BIOLOGICAL VARIATION DRIVEN BY RISK-ASSOCIATED SNPS AND POTENTIAL SEX DIFFERENCES |
| Giovanni Frisoni | Italy | THE PROBABILISTIC AMYLOID CASCADE HYPOTHESIS: EVIDENCE OF VALIDITY AND IMPLICATIONS |
| Lutz Frolich | Germany | CHARACTERIZATION OF SNAP - BIOMARKER AND CLINICAL FINDINGS |
| James Galvin | USA | MECHANISMS OF COGNITIVE RESILIENCE AND BRAIN HEALTH |
| Angela Genge | Canada | CLINICAL TRIAL UPDATE IN ALS |
| Klaus Gerwert | Germany | MISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED-BIOMARKER FOR PARKINSON’S DISEASE |
| Todd Golde | USA | HOW AMYLOID TALKS TO TAU |
| Lea Grinberg | USA | UNDERSTANDING NEURODEGENERATIVE DISEASES TODAY: LESSONS FROM CLINICOPATHOLOGICAL CORRELATIONS AND THE ONGOING ROLE OF NEUROPATHOLOGY IN THE BIOMARKER AGE |
| Christian Haass | Germany | THERAPEUTIC MODULATION OF MICROGLIA |
| Oskar Hansson | Sweden | OPTIMIZING DIAGNOSTIC WORKFLOWS FOR ACCURATE DETECTION OF STAGE 1–2 (PRECLINICAL) ALZHEIMER’S DISEASE |
| Elizabeth Head | USA | AGING AND ALZHEIMER DISEASE IN DOWN SYNDROME: UPDATES FROM STUDIES OF NEUROPATHOLOGY |
| Makato Higuchi | Japan | IMAGING THE INTERPLAY BETWEEN PROTEIN AGGREGATIONS AND NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES |
| Henne Holstege | Netherlands | NEUROPATHOLOGY IN COGNITIVELY HEALTHY CENTENARIANS: HOW DID AGE AFFECT THEIR BRAIN? |
| David Holtzman | USA | EFFECTS OF ANTI-CXCR3 ANTIBODY BLOCKADE ON TAU-MEDIATED NEURODEGENERATION |
| Soyon Hong | UK | ASTROCYTE-MICROGLIA CROSSTALK AT THE SYNAPSE IN ALZHEIMER'S DISEASE |
| Bradley Hyman | USA | MECHANISMS OF TAU TOXICITY IN ALZHEIMER DISEASE |
| Costantino Iadecola | USA | UNTANGLING MIXED DEMENTIA: A NEUROVASCULAR LENS ON PATHOBIOLOGY |
| Ole Isacson | USA | CAN APOE AND ENDOLYSOSOMAL DYSFUNCTION CREATE THE MAJOR PARKINSON’S, LEWY BODY DEMENTIA, AND ALZHEIMER DISEASE PATHOLOGIES? |
| Takeshi Iwatsubo | Japan | PLASMA BIOMARKERS AND PET IMAGING IN COHORT AND REGISTRY STUDIES IN JAPAN |
| Joanna Jankowsky | USA | NEURONAL SUBTYPE GOVERNS AMYLOID STRUCTURE, CELLULAR RESPONSE, AND COGNITIVE OUTCOME IN GENETICALLY TARGETED APP MOUSE MODELS |
| Sterling Johnson | USA | TEMPORAL INSIGHTS FROM AD AND NON AD BIOMARKERS ON THE SPEED OF PROGRESSION THROUGH THE CLINICAL STAGES OF AD |
| Miia Kivipelto | Sweden | LATEST FINDINGS FROM WORLD-WIDE FINGERS: EFFICACY OF TAILORED MULTIDOMAIN INTERVENTIONS FOR PREVENTION OF COGNITIVE DECLINE AND DEMENTIA |
| Loote Bjerre Knudsen | Netherlands | GLP-1 IN ALZHEIMER'S DISEASE |
| Dimitri Krainc | USA | GENETIC MODIFIERS OF LYSOSOMAL FUNCTION IN PARKINSON'S AND RELATED DISORDERS |
| Frank Laferla | USA | MODEL-AD: NEW INSIGHTS & ADVANCES |
| Virginia Lee | USA | TRANSMISSION OF MISFOLDED PROTEINS IN NEURODEGENERATIVE DISORDERS: A COMMON MECHANISM OF DISEASE PROGRESSION |
| Cynthia Lemere | USA | MECHANISMS OF ARIA IN AMYLOID MOUSE MODELS |
| Stuart A. Lipton | USA | MITOCHONDRIAL METABOLIC BYPASS RESCUES ABERRANT S-NITROSYLATION-INDUCED TCA CYCLE INHIBITION, ENERGY COMPROMISE, AND SYNAPSE LOSS IN ALZHEIMER’S DISEASE AND LEWY BODY DEMENTIA HUMAN iPSC NEURONS |
| Gill Livingston | USA | CAN WE PREVENT DEMENTIA? |
| Frank Longo | USA | MODULATION OF THE P75 NEUROTROPHIN RECEPTOR ATTENUATES TAU PHOSPHORYLATION AND PROMOTES SYNAPTIC RESILIENCE IN ALZHEIMER’S DISEASE |
| Kenneth Marek | USA | IMAGING AND FLUID BIOMARKERS IN NSD IN PPMI |
| Pamela McLean | USA | MOLECULAR PROFILING OF EXTRACELLULAR VESICLES HARBORING SEED-COMPETENT ALPHA-SYNUCLEIN IN LBD |
| Michelle Mielke | USA | UPDATES ON IMPLEMENTING COGNITIVE TESTING AND BLOOD-BASED AD BIOMARKERS IN PRIMARY CARE |
| Inhee Mook-Jung | Korea, Republic of | FROM GUT TO BRAIN: INVESTIGATING LPS-MEDIATED NEUROINFLAMMATION IN ALZHEIMER'S DISEASE |
| Asuka Morizane | Japan | IPSC-BASED CELL THERAPY FOR PARKINSON’S DISEASE: KYOTO TRIAL |
| John Morris | USA | MEASURING POTENTIAL BENEFIT OF AMYLOID-TARGETING TREATMENTS IN A MEMORY DISORDERS CLINIC |
| Ulrike Müller | Germany | AAAV-MEDIATED OR LIPOSOMAL DELIVERY OF A NEUROTROPHIC PEPTIDE DERIVED FROM SOLUBLE APPS AS A SYNAPTIC PLASTICITY ENHANCING THERAPEUTIC STRATEGY FOR AD |
| Melissa Murray | USA | TRANSFORMATIVE NEUROPATHOLOGY OF MAPT: MACHINE LEARNING UNCOVERS TAU LESION SIGNATURES PREDICTIVE OF MUTATION STATUS |
| Henrietta Nielsen | Sweden | HEPTIC APOE SIGNATURES AND RELEVANCE TO NEURODEGENERATIVE DISEASE |
| Agneta Nordberg | Sweden | TRACKING EARLY AD PATHOLOGY BY MULTIMODAL PET, FLUID BIOMARKERS AND COGNITITION IN SPORADIC AD, ADAD AND DOWN AD |
| Sid O’Bryant | USA | ALZHEIMER'S DISEASE BIOMARKERS AMONG DIVERSE POPULATIONS - FINDINGS FROM THE HABS-HD STUDY |
| Kate Onuska | Canada | CHOLINERGIC AND NORADRENERGIC VULNERABILITY IN AGING AND PRESYMPTOMATIC ALZHEIMER'S DISEASE |
| Tiago Outeiro | Germany | MOLECULAR EFFECTS OF NOVEL ALPHA-SYNUCLEIN MUTATIONS |
| Ronald Petersen | USA | PRECLINICAL POPULATIONS: RATES OF PROGRESSION TO MCI |
| Werner Poewe | Austria | ONLINE SCREENING FOR PD RISK - CROSS-SECTIONAL RESULTS FROM THE HEBA STUDY |
| Laura Ranum | USA | REPEAT ASSOCIATED NON-AUG (RAN) PROTEINS IN RARE & COMMON NEUROLOGICAL DISEASES: MOLECULAR INSIGHTS AND THERAPEUTIC OPPORTUNITIES |
| Stephen Salloway | USA | SAFE USE OF AMYLOID-LOWERING ANTIBODIES |
| Philip Scheltens | Netherlands | PRIMARY PREVENTION OF AD: FACT OR FICTION? |
| Michael Schlossmacher | Canada | PREDICTING THE ONSET OF PARKINSON'S: ARE WE THERE YET? |
| Taylor Schmitz | Canada | CHOLINERGIC SYNAPTIC PLASTICITY SHAPES RESILIENCE AND VULNERABILITY TO TAU |
| Julia Schumacher | Germany | PEDUNCULOPONTINE-THALAMIC CHOLINERGIC PROJECTIONS IN RAPID EYE MOVEMENT SLEEP BEHAVIOUR DISORDER |
| Menachem Segal | Israel | THE PDE5 INHIBITOR TADALAFIL COUNTERACTS AD-SYMPTOMS: MECHANISM OF ACTION IN MUTANT PRESENILIN TRANSFECTED NEURONS |
| Hayley Shanks | Canada | INDIVIDUALIZED PROFILES OF TAU SPREADING, CHOLINERGIC VULNERABILITY, AND CLINICAL CONVERSION: A LONGITUDINAL, MULTIMODAL IMAGING STUDY |
| Jie Shen | USA | ESSENTIAL FUNCTION OF MICROGLIAL LRRK2 IN DOPAMINERGIC NEURONAL SURVIVAL IN THE AGING MOUSE BRAIN |
| Jung-Hwan Shin | Korea, Republic of | CELL TYPE SPECIFIC MODULATION OF STN IN PARKINSONISM |
| Tamara Shiner | Israel | ALPHA-SYNUCLEIN CO-PATHOLOGY IN A REAL-WORLD EARLY ALZHEIMER’S DISEASE COHORT |
| Sam Sisodia | USA | SEX-SPECIFIC MODULATION OF AD-LIKE PHENOTYPES IN MOUSE MODELS |
| Beka Solomon | Israel | TAU PHOSPHORYLATION HIGHLIGHT THE THERAPEUTIC ADVANTAGE OF DRUGS THAT TARGET AD’S INTRACELLULAR PATHOLOGIES. |
| Mona Soreq | Israel | TRANSFER RNA FRAGMENTS AS EARLY PREDICTORS OF AD AND PD |
| Maria Grazia Spillantini | UK | ALPHA-SYNUCLEIN SPREADING FROM PERIPHERY TO THE BRAIN |
| Beth Stevens | USA | PRE-RECORDED: COPATHOLOGIES IN ALZHEIMER’S AND PARKINSON’S: IDENTIFYING GENETIC AND ENVIRONMENTAL MODIFIERS OF MICROGLIAL MULTITASKING |
| Fabrizio Stocchi | Italy | CAN WE PREVENT PARKINSON'S DISEASE? |
| Peter St.George-Hyslop | Canada | INTRACELLULAR AND EXTRACELLULAR CD33 SIGNALLING |
| Rudy Tanzi | USA | THE ROLE OF PERIPHERAL IMMUNE CELLS IN ALZHEIMER'S DISEASE PATHOGENESIS |
| Niccolo Tesi | Netherlands | STRUCTURAL VARIANTS SHAPE GENETIC RISK HAPLOTYPES IN ALZHEIMER’S DISEASE |
| Charlotte Teunissen | Netherlands | TRACKING INFLAMMATION BY FLUID BIOMARKERS DURING TREATMENT OF AD PATIENTS |
| Li-Huei Tsai | USA | APOE4 ALTERS LIPID HOMEOSTASIS VIA LIPID-MODIFYING ENZYMES AND DYSREGULATED SIGNALING PATHWAYS |
| Susanne van Veluw | USA | CEREBRAL AMYLOID ANGIOPATHY |
| Robert Vassar | USA | MECHANISTIC INSIGHTS INTO THE CONNECTION BETWEEN ABETA AND TAU |
| Lis de Weerd | Germany | TREM2 AGONISM INDUCES MICROGLIAL AND CSF PROTEOME CHANGES IN AN AGE-DEPENDENT MANNER |
| Rimona S Weil | UK | ADVANCED MRI TO PREDICT AND MONITOR DEMENTIA IN PARKINSON'S |
| Michael Weiner | USA | VOICE ROBOTS FOR AUTOMATED AI POWERED ASSESSMENTS: THE ADNI PERSPECTIVE |
| Cheryl Wellington | Canada | ALAMAR NULISA PROFILING IDENTIFIES IMMUNE CHECKPOINTS AS AGE-ASSOCIATED PLASMA BIOMARKERS IN HUMAN APOE MOUSE MODELS |
| Donna Wilcock | USA | UNDERSTANDING MECHANISMS OF ARIA - INSIGHTS FROM HUMAN AND MOUSE |
| Lisha Wang | Sweden | PROTACS REDUCES PHOSPHO-TAU LEVELS IN AD |
| Christiane Wrann | USA | HARNESSING THE PROTECTIVE EFFECTS OF EXERCISE TO COMBAT ALZHEIMER'S DISEASE |
| Henrik Zetterberg | Sweden | UPDATE ON BIOMARKERS FOR TDP-43 PROTEINOPATHY AND LOSS OF FUNCTION |
